Medication "Pradax". Instruction and description

Medication "Pradax" belongs to the category of anticoagulants, direct (immediate) thrombin inhibitors. The active substance is dabigatran ethexilate. After penetration into the body, rapid absorption is noted. The medication is allocated by the kidneys (mainly). A small amount leaves through the intestine. The "Pradax" remedy is a drug that promotes the elongation of partial activated thromboplastin time.

Appointment

Medication "Pradax" instruction recommends for the prevention of venous thromboembolism in patients who undergone extensive orthopedic operations.

Dosing regimen

Means to drink on an empty stomach or with food. To prevent venous thromboembolism, the recommended dose is 220 mg once a day (two 110 mg capsules). If the patient has a moderate disorder of kidney function, the risk of bleeding increases. In connection with this, such a patient "Pradaksa" (instructions for use contains such data) is prescribed for 150 mg per day (2 capsules of 75 milligrams each). After the implementation of hip replacement, therapy should be started 1-4 hours after the end of the intervention. The initial dose is a capsule of 110 mg. Subsequently, a gradual increase in the amount of medicament to 2 caps. 2 p / day. Duration of admission is ten days. With unstable hemostatic parameters, therapy with Pradax (the instruction recommends this) should be postponed. In case of delay in starting treatment, the dosage is 2 caps. Once a day.

Adverse Reactions

Medication "Pradaksa" (the instruction warns about this) can cause disorders of the liver, changes in its performance of a transient type. Negative consequences include bleeding, hemorrhages, hematomas. The agent can provoke thrombocytopenia, epitaxy, anemia.

Contraindications

Medication "Pradax" instruction does not recommend for hemorrhagic syndrome, kidney failure of severe course, intolerance of one of the components. Contraindications include organic lesions due to clinically significant bleeding, including after hemorrhagic stroke in the last six months before the start of therapy. The medication is not assigned to patients with an established catheter in the spinal canal or epidural space, and also during the first sixty minutes after its elimination. To contraindications to the appointment of the means of "Pradax" (the instruction indicates this) include lactation, pregnancy. Do not use a medication before the age of eighteen.

additional information

When the capsules are released, they should not be squeezed out of the foil. The medicine is removed from the blister, peeling the package in the direction indicated by the arrows. It is recommended to remove the foil so that it is convenient to get the capsules. With the simultaneous use of the Pradaksa (the instruction indicates this) with medications that affect coagulation processes or hemostasis, including with vitamin K antagonists, there is probably a significant increase in the risk of bleeding.